Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of newly diagnosed childhood AML using a timed-sequential remission induction and consolidation followed by single dose melphalan with peripheral stem cell rescue: a POG pilot study

Next Previous
X
Search
Trial Profile

Treatment of newly diagnosed childhood AML using a timed-sequential remission induction and consolidation followed by single dose melphalan with peripheral stem cell rescue: a POG pilot study

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics; Asparaginase; Cytarabine; Daunorubicin; Melphalan; Tioguanine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions

    • Most Recent Events

    • 28 Jul 2014 Biomarkers information updated
    • 23 Jul 2008 Estimated patient number amended from 20 to 30 to be consistent with NCT
    • 16 Nov 2007 Results were reported at the Proceedings of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top